Sign in

Trial result ·

TIM3 Blockade with Hypomethylating Therapy Restores NK Cell and Cytotoxic CD4+ T-cell Activity in Patients with AML or MDS.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This early-phase trial tested sabatolimab, a drug that blocks TIM3. It was given with decitabine, a hypomethylating drug. The patients had acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The study covered 14 patients. Cells from 6 of them were studied closely. The team used single-cell RNA and T-cell receptor sequencing. They also ran lab co-culture tests. Some patients respond fully to checkpoint drugs. So AML and MDS can react to immune therapy.

What they found

TIM3 was found widely on NK cells, myeloid cells and T cells. CTLA4 and PD1 were limited to T cells. Treatment expanded cytotoxic NK cell groups. It also boosted interferon signalling. Very few bone marrow CD8+ T cells looked exhausted. In responders, treatment mainly grew small CD8+ T-cell clones. Responders also had more cytotoxic CD4+ T cells and B cells. A patient already had CD4+ T-cell large granular lymphocyte leukemia (T-LGLL). This patient had a complete response lasting 23 months. Many of the patient's lymphocytes were T-LGLL cells. Their receptor could recognise the patient's own leukemia cells.

What it means for patients

The authors say anti-TIM3 with decitabine seems to engage a distinct immune mechanism. It differs from anti-PD-1 and anti-CTLA4. It mainly expands NK cell and CD4+ T-cell groups.

Why it is not certain yet

The analysis covered 14 patients. Only 6 had single-cell sequencing. The authors call the results suggestive. The abstract gives no other limits. A single trial can only show so much.

Source

TIM3 Blockade with Hypomethylating Therapy Restores NK Cell and Cytotoxic CD4+ T-cell Activity in Patients with AML or MDS.

PubMed · PMID 42599272

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Acute myeloid leukaemia publications